{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T11:28:47Z","timestamp":1788607727809,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Immunol"],"DOI":"10.1038\/s41423-026-01418-7","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T02:23:31Z","timestamp":1777515811000},"page":"686-700","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["De novo engineered disulfide bond supersedes native interchain linkage to enhance TCR pairing and anti-tumor efficacy in T cell therapy"],"prefix":"10.1038","volume":"23","author":[{"given":"Dan","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqi","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Rui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangna","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"1418_CR1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adf3700","volume":"9","author":"E Baulu","year":"2023","unstructured":"Baulu E, Gardet C, Chuvin N, Depil S. TCR-engineered T cell therapy in solid tumors: state of the art and perspectives. Sci Adv. 2023;9:eadf3700.","journal-title":"Sci Adv"},{"key":"1418_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107603","volume":"214","author":"M Poorebrahim","year":"2020","unstructured":"Poorebrahim M, Abazari MF, Sadeghi S, Mahmoudi R, Kheirollahi A, Askari H, et al. Genetically modified immune cells targeting tumor antigens. Pharmacol Ther. 2020;214:107603.","journal-title":"Pharmacol Ther"},{"key":"1418_CR3","doi-asserted-by":"crossref","unstructured":"Gaissmaier L, Elshiaty M, Christopoulos P. Breaking bottlenecks for the TCR therapy of cancer. Cells. 2020;9:2095.","DOI":"10.3390\/cells9092095"},{"key":"1418_CR4","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","volume":"403","author":"SP D\u2019Angelo","year":"2024","unstructured":"D\u2019Angelo SP, Araujo DM, Abdul Razak AR, Agulnik M, Attia S, Blay JY, et al. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet. 2024;403:1460\u201371.","journal-title":"Lancet"},{"key":"1418_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101133","volume":"4","author":"Q Pan","year":"2023","unstructured":"Pan Q, Weng D, Liu J, Han Z, Ou Y, Xu B, et al. Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A *02:01 patients with advanced soft tissue sarcoma. Cell Rep Med. 2023;4:101133.","journal-title":"Cell Rep Med"},{"key":"1418_CR6","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3350\/cmh.2024.0058","volume":"30","author":"X Wan","year":"2024","unstructured":"Wan X, Wisskirchen K, Jin T, Yang L, Wang X, Wu X, et al. Genetically modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting. Clin Mol Hepatol. 2024;30:735\u201355.","journal-title":"Clin Mol Hepatol"},{"key":"1418_CR7","doi-asserted-by":"crossref","unstructured":"Wermke M, Araujo WADM, Busse A, Chatterjee M, Hernandez-Aya LF, Hilf N, et al. Phase 1 clinical update of IMA203, an autologous TCR-T targeting PRAME in patients with PD1 refractory metastatic melanoma. ASCO Annual Meeting. J Clin Oncol. 2025;43:Number 16_suppl.2508.","DOI":"10.1200\/JCO.2025.43.16_suppl.2508"},{"key":"1418_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T-cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69.","journal-title":"Blood Cancer J"},{"key":"1418_CR9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","volume":"20","author":"CL Flugel","year":"2023","unstructured":"Flugel CL, Majzner RG, Krenciute G, Dotti G, Riddell SR, Wagner DL, et al. Overcoming on-target, off-tumor toxicity of CAR T-cell therapy for solid tumors. Nat Rev Clin Oncol. 2023;20:49\u201362.","journal-title":"Nat Rev Clin Oncol"},{"key":"1418_CR10","doi-asserted-by":"publisher","first-page":"6273","DOI":"10.7150\/thno.76854","volume":"12","author":"Z Liu","year":"2022","unstructured":"Liu Z, Zhou Z, Dang Q, Xu H, Lv J, Li H, et al. Immunosuppression in tumor immune microenvironment and its optimization from CAR-T-cell therapy. Theranostics. 2022;12:6273\u201390.","journal-title":"Theranostics"},{"key":"1418_CR11","doi-asserted-by":"publisher","first-page":"e1006874","DOI":"10.1371\/journal.pcbi.1006874","volume":"15","author":"T Dupic","year":"2019","unstructured":"Dupic T, Marcou Q, Walczak AM, Mora T. Genesis of the \u03b1\u03b2 T-cell receptor. PLoS Comput Biol. 2019;15:e1006874.","journal-title":"PLoS Comput Biol"},{"key":"1418_CR12","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40164-022-00291-0","volume":"11","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Liu Z, Wei W, Li Y. TCR engineered T cells for solid tumor immunotherapy. Exp Hematol Oncol. 2022;11:38.","journal-title":"Exp Hematol Oncol"},{"key":"1418_CR13","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1242\/dmm.018036","volume":"8","author":"M Sharpe","year":"2015","unstructured":"Sharpe M, Mount N. Genetically modified T cells in cancer therapy: opportunities and challenges. Dis Model Mech. 2015;8:337\u201350.","journal-title":"Dis Model Mech"},{"key":"1418_CR14","doi-asserted-by":"publisher","first-page":"188ra74","DOI":"10.1126\/scitranslmed.3005452","volume":"5","author":"GP Morris","year":"2013","unstructured":"Morris GP, Uy GL, Donermeyer D, Dipersio JF, Allen PM. Dual receptor T cells mediate pathologic alloreactivity in patients with acute graft-versus-host disease. Sci Transl Med. 2013;5:188ra74.","journal-title":"Sci Transl Med"},{"key":"1418_CR15","doi-asserted-by":"publisher","first-page":"188fs21","DOI":"10.1126\/scitranslmed.3006431","volume":"5","author":"BG Vincent","year":"2013","unstructured":"Vincent BG, Serody JS. One is better than two: TCR pairing and GVHD. Sci Transl Med. 2013;5:188fs21.","journal-title":"Sci Transl Med"},{"key":"1418_CR16","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/nm.2128","volume":"16","author":"GM Bendle","year":"2010","unstructured":"Bendle GM, Linnemann C, Hooijkaas AI, Bies L, de Witte MA, Jorritsma A, et al. Lethal graft-versus-host disease in mouse models of T-cell receptor gene therapy. Nat Med. 2010;16:565\u201370.","journal-title":"Nat Med"},{"key":"1418_CR17","doi-asserted-by":"publisher","first-page":"10972","DOI":"10.1073\/pnas.1005802107","volume":"107","author":"MM van Loenen","year":"2010","unstructured":"van Loenen MM, de Boer R, Amir AL, Hagedoorn RS, Volbeda GL, Willemze R, et al. Mixed T-cell receptor dimers harbor potentially harmful neoreactivity. Proc Natl Acad Sci USA. 2010;107:10972\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1418_CR18","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1182\/blood-2006-03-013318","volume":"109","author":"MH Heemskerk","year":"2007","unstructured":"Heemskerk MH, Hagedoorn RS, van der Hoorn MA, van der Veken LT, Hoogeboom M, Kester MG, et al. Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. Blood. 2007;109:235\u201343.","journal-title":"Blood"},{"key":"1418_CR19","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1002\/ajh.26708","volume":"97","author":"G Liu","year":"2022","unstructured":"Liu G, Chen H, Cao X, Jia L, Rui W, Zheng H, et al. Efficacy of pp65-specific TCR-T-cell therapy in treating cytomegalovirus infection after hematopoietic stem cell transplantation. Am J Hematol. 2022;97:1453\u201363.","journal-title":"Am J Hematol"},{"key":"1418_CR20","doi-asserted-by":"crossref","unstructured":"Liu Y, Liu G, Wang J, Zheng ZY, Jia L, Rui W, et al. Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors. Sci Transl Med. 2021;13:eabb5191.","DOI":"10.1126\/scitranslmed.abb5191"},{"key":"1418_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1126\/science.274.5285.209","volume":"274","author":"KC Garcia","year":"1996","unstructured":"Garcia KC, Degano M, Stanfield RL, Brunmark A, Jackson MR, Peterson PA, et al. An alphabeta T-cell receptor structure at 2.5 A and its orientation in the TCR-MHC complex. Science. 1996;274:209\u201319.","journal-title":"Science"},{"key":"1418_CR22","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.4161\/hv.24051","volume":"9","author":"B Berdien","year":"2013","unstructured":"Berdien B, Reinhard H, Meyer S, Sp\u00f6ck S, Kr\u00f6ger N, Atanackovic D, et al. Influenza virus-specific TCR-transduced T cells as a model for adoptive immunotherapy. Hum Vaccin Immunother. 2013;9:1205\u201316.","journal-title":"Hum Vaccin Immunother"},{"key":"1418_CR23","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1158\/0008-5472.CAN-06-3986","volume":"67","author":"CJ Cohen","year":"2007","unstructured":"Cohen CJ, Li YF, El-Gamil M, Robbins PF, Rosenberg SA, Morgan RA. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res. 2007;67:3898\u2013903.","journal-title":"Cancer Res"},{"key":"1418_CR24","doi-asserted-by":"publisher","first-page":"8878","DOI":"10.1158\/0008-5472.CAN-06-1450","volume":"66","author":"CJ Cohen","year":"2006","unstructured":"Cohen CJ, Zhao Y, Zheng Z, Rosenberg SA, Morgan RA. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR\/CD3 stability. Cancer Res. 2006;66:8878\u201386.","journal-title":"Cancer Res"},{"key":"1418_CR25","doi-asserted-by":"publisher","first-page":"5852","DOI":"10.1158\/1078-0432.CCR-10-1280","volume":"16","author":"JL Davis","year":"2010","unstructured":"Davis JL, Theoret MR, Zheng Z, Lamers CH, Rosenberg SA, Morgan RA. Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials. Clin Cancer Res. 2010;16:5852\u201361.","journal-title":"Clin Cancer Res"},{"key":"1418_CR26","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1182\/blood-2006-05-023069","volume":"109","author":"J Kuball","year":"2007","unstructured":"Kuball J, Dossett ML, Wolfl M, Ho WY, Voss RH, Fowler C, et al. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood. 2007;109:2331\u20138.","journal-title":"Blood"},{"key":"1418_CR27","doi-asserted-by":"publisher","first-page":"5538","DOI":"10.4049\/jimmunol.1103020","volume":"188","author":"A Haga-Friedman","year":"2012","unstructured":"Haga-Friedman A, Horovitz-Fried M, Cohen CJ. Incorporation of transmembrane hydrophobic mutations in the TCR enhance its surface expression and T-cell functional avidity. J Immunol. 2012;188:5538\u201346.","journal-title":"J Immunol"},{"key":"1418_CR28","doi-asserted-by":"publisher","first-page":"391","DOI":"10.4049\/jimmunol.180.1.391","volume":"180","author":"RH Voss","year":"2008","unstructured":"Voss RH, Willemsen RA, Kuball J, Grabowski M, Engel R, Intan RS, et al. Molecular design of the Calphabeta interface favors specific pairing of introduced TCRalphabeta in human T cells. J Immunol. 2008;180:391\u2013401.","journal-title":"J Immunol"},{"key":"1418_CR29","doi-asserted-by":"crossref","unstructured":"Bethune MT, Gee MH, Bunse M, Lee MS, Gschweng EH, Pagadala MS, et al. Domain-swapped T-cell receptors improve the safety of TCR gene therapy. eLife. 2016;5:e19095.","DOI":"10.7554\/eLife.19095"},{"key":"1418_CR30","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1038\/sj.gt.3301253","volume":"7","author":"RA Willemsen","year":"2000","unstructured":"Willemsen RA, Weijtens ME, Ronteltap C, Eshhar Z, Gratama JW, Chames P, et al. Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR. Gene Ther. 2000;7:1369\u201377.","journal-title":"Gene Ther"},{"key":"1418_CR31","doi-asserted-by":"crossref","unstructured":"Jin BY, Campbell TE, Draper, LM, Stevanovic S, Weissbrich B, Yu Z, et al. Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model. JCI Insight. 2018;3:e99488.","DOI":"10.1172\/jci.insight.99488"},{"key":"1418_CR32","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","volume":"386","author":"R Leidner","year":"2022","unstructured":"Leidner R, Sanjuan Silva N, Huang H, Sprott D, Zheng C, Shih YP, et al. Neoantigen T-cell receptor gene therapy in pancreatic cancer. N Engl J Med. 2022;386:2112\u20139.","journal-title":"N Engl J Med"},{"key":"1418_CR33","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1158\/2326-6066.CIR-22-0040","volume":"10","author":"SP Kim","year":"2022","unstructured":"Kim SP, Vale NR, Zacharakis N, Krishna S, Yu Z, Gasmi B, et al. Adoptive cellular therapy with autologous tumor-infiltrating lymphocytes and T-cell receptor-engineered T cells targeting common p53 neoantigens in human solid tumors. Cancer Immunol Res. 2022;10:932\u201346.","journal-title":"Cancer Immunol Res"},{"key":"1418_CR34","doi-asserted-by":"publisher","first-page":"E6649","DOI":"10.1073\/pnas.1611445113","volume":"113","author":"L Krshnan","year":"2016","unstructured":"Krshnan L, Park S, Im W, Call MJ, Call ME. A conserved alphabeta transmembrane interface forms the core of a compact T-cell receptor-CD3 structure within the membrane. Proc Natl Acad Sci USA. 2016;113:E6649\u201358.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1418_CR35","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/s41586-019-1537-0","volume":"573","author":"D Dong","year":"2019","unstructured":"Dong D, Zheng L, Lin J, Zhang B, Zhu Y, Li N, et al. Structural basis of assembly of the human T-cell receptor-CD3 complex. Nature. 2019;573:546\u201352.","journal-title":"Nature"},{"key":"1418_CR36","doi-asserted-by":"publisher","first-page":"6223","DOI":"10.4049\/jimmunol.0902055","volume":"184","author":"D Sommermeyer","year":"2010","unstructured":"Sommermeyer D, Uckert W. Minimal amino acid exchange in human TCR constant regions fosters improved function of TCR gene-modified T cells. J Immunol. 2010;184:6223\u201331.","journal-title":"J Immunol"},{"key":"1418_CR37","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1182\/blood-2007-02-075010","volume":"110","author":"A Jorritsma","year":"2007","unstructured":"Jorritsma A, Gomez-Eerland R, Dokter M, van de Kasteele W, Zoet YM, Doxiadis II, et al. Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. Blood. 2007;110:3564\u201372.","journal-title":"Blood"},{"key":"1418_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12441-w","volume":"10","author":"S Thomas","year":"2019","unstructured":"Thomas S, Mohammed F, Reijmers RM, Woolston A, Stauss T, Kennedy A, et al. Framework engineering to produce dominant T-cell receptors with enhanced antigen-specific function. Nat Commun. 2019;10:4451.","journal-title":"Nat Commun"},{"key":"1418_CR39","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.molimm.2008.09.021","volume":"46","author":"SA Richman","year":"2009","unstructured":"Richman SA, Aggen DH, Dossett ML, Donermeyer DL, Allen PM, Greenberg PD, et al. Structural features of T-cell receptor variable regions that enhance domain stability and enable expression as single-chain ValphaVbeta fragments. Mol Immunol. 2009;46:902\u201316.","journal-title":"Mol Immunol"},{"key":"1418_CR40","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19:185\u201399.","journal-title":"Nat Rev Drug Discov"},{"key":"1418_CR41","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","volume":"187","author":"X Wang","year":"2024","unstructured":"Wang X, Wu X, Tan B, Zhu L, Zhang Y, Lin L, et al. Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. Cell. 2024;187:4890\u2013904.e9.","journal-title":"Cell"},{"key":"1418_CR42","doi-asserted-by":"crossref","unstructured":"Wang X, Zhang Y, Wang H, Wu X, He C, Lin S, et al. Allogeneic CD19-targeting T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial. Nat Med. 2025;31:3713\u201324.","DOI":"10.1038\/s41591-025-03899-x"},{"key":"1418_CR43","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-14-2708","volume":"21","author":"PF Robbins","year":"2015","unstructured":"Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res. 2015;21:1019\u201327.","journal-title":"Clin Cancer Res"},{"key":"1418_CR44","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1172\/JCI123791","volume":"129","author":"P Malekzadeh","year":"2019","unstructured":"Malekzadeh P, Pasetto A, Robbins PF, Parkhurst MR, Paria BC, Jia L, et al. Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers. J Clin Invest. 2019;129:1109\u201314.","journal-title":"J Clin Invest"},{"key":"1418_CR45","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1158\/2326-6066.CIR-15-0188","volume":"4","author":"QJ Wang","year":"2016","unstructured":"Wang QJ, Yu Z, Griffith K, Hanada K, Restifo NP, Yang JC. Identification of T-cell receptors targeting KRAS-mutated human tumors. Cancer Immunol Res. 2016;4:204\u201314.","journal-title":"Cancer Immunol Res"},{"key":"1418_CR46","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1097\/CAD.0b013e32833f5d68","volume":"21","author":"K Nakano","year":"2010","unstructured":"Nakano K, Ishiguro T, Konishi H, Tanaka M, Sugimoto M, Sugo I, et al. Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization. Anticancer Drugs. 2010;21:907\u201316.","journal-title":"Anticancer Drugs"},{"key":"1418_CR47","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1038\/gt.2008.90","volume":"15","author":"S Yang","year":"2008","unstructured":"Yang S, Cohen CJ, Peng PD, Zhao Y, Cassard L, Yu Z, et al. Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. Gene Ther. 2008;15:1411\u201323.","journal-title":"Gene Ther"},{"key":"1418_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114949","volume":"43","author":"D Huang","year":"2024","unstructured":"Huang D, Li Y, Rui W, Sun K, Zhou Z, Lv X, et al. TCR-mimicking STAR conveys superior sensitivity over CAR in targeting tumors with low-density neoantigens. Cell Rep. 2024;43:114949.","journal-title":"Cell Rep"}],"container-title":["Cellular & Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41423-026-01418-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41423-026-01418-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41423-026-01418-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T22:02:27Z","timestamp":1780178547000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41423-026-01418-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":48,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["1418"],"URL":"https:\/\/doi.org\/10.1038\/s41423-026-01418-7","relation":{},"ISSN":["2042-0226"],"issn-type":[{"value":"2042-0226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"31 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DS, JW, and GL have applied for a\u00a0patent related to the subject of this paper. All the other authors declare that they have no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}